CELC Quote, Financials, Valuation and Earnings

Cidara Therapeutics, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of -30201.66%. Celcuity, Inc.'s return on equity of -158.5% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Celcuity, Inc. has a consensus price target of $110.50, signalling upside risk potential of 8.07%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.32%. Given that Celcuity, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Celcuity, Inc. is more attractive than Cidara Therapeutics, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Biosciences, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Celcuity, Inc. has a consensus price target of $110.50, signalling upside risk potential of 8.07%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $49.18 which suggests that it could grow by 26.5%. Given that Cogent Biosciences, Inc. has higher upside potential than Celcuity, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.519%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Celcuity, Inc. has a consensus price target of $110.50, signalling upside risk potential of 8.07%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 75.37%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Replimune Group, Inc.'s return on equity of -82.53%.

Celcuity, Inc. has a consensus price target of $110.50, signalling upside risk potential of 8.07%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 26.22%. Given that Replimune Group, Inc. has higher upside potential than Celcuity, Inc., analysts believe Replimune Group, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.